Sonya Del Tredici and John Keenan
Sonya Del Tredici and John Keenan
51-60 Round-Up
51-60 Round-Up
51-60 Round-Up
Monday 25th August 2025
Explore key findings from articles 51-60 on addiction recovery, buprenorphine, methadone, and methamphetamine treatment trials.
58 minutes
hopeful
challenging
informative
analytical
reflective
About this podcast
Author:
Sonya Del Tredici and John Keenan
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Navigating Intimate Relationships
Family Recovery from Addiction
Nutritional Pathways to Recovery
Episodes:
77 (View all)
Do you want to link to this podcast?
Get the buttons here!Addiction Insights: Articles 51-60 Recap
Episode Overview
- Non-drug activities can enhance recovery outcomes.
- Buprenorphine challenges in fentanyl withdrawal.
- Methadone shows lower discontinuation risk than buprenorphine.
- Higher buprenorphine doses may reduce urgent care visits.
- Lisdexamphetamine trial for methamphetamine use shows no efficacy.
Recovery is a process of growth and development, of being honest with oneself, and of taking responsibility for the things one can change.
In this episode, the hosts delve into ten recent articles related to addiction medicine, providing listeners with concise summaries and insights. Beginning with Article 51, the discussion centers around the importance of non-drug-related activities in aiding recovery from substance use. The study highlights how fun activities such as recreational or educational pursuits can significantly lower the chances of relapse.
This aligns with the understanding that alcohol and drugs provide rewarding effects, and when individuals lack alternative rewarding activities, the allure of substances increases. The episode continues with Article 52, which examines the phenomenon of buprenorphine-precipitated withdrawal in patients who use fentanyl. This article brings to light the challenges faced by clinicians in managing withdrawal symptoms when patients transition from fentanyl to buprenorphine, emphasizing the need for careful assessment and management.
Article 53 compares methadone and buprenorphine/naloxone in the treatment of opioid use disorder. The study suggests methadone may have a lower risk of treatment discontinuation than buprenorphine, especially for first-time users, highlighting the importance of tailoring treatment plans to individual patient needs and circumstances. The discussion on Article 54 addresses the impact of high daily doses of buprenorphine on urgent healthcare visits.
Findings indicate that higher doses could potentially delay or reduce visits, although discontinuation of the drug might lead to patient disengagement from healthcare systems. Finally, the hosts review a study on lisdexamphetamine as a treatment for methamphetamine dependence. Despite initial promise, the trial results showed no significant difference between lisdexamphetamine and placebo, suggesting that alternative approaches may be needed to address stimulant use disorders.
Throughout the episode, the hosts provide their own insights and reflections, fostering an engaging and informative discussion for listeners interested in addiction medicine.